Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
SEM vs UHS vs HCA vs ENSG vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
SEM vs UHS vs HCA vs ENSG vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $2.04B | $10.68B | $95.95B | $10.18B | $17.01B |
| Revenue (TTM) | $5.52B | $17.76B | $75.60B | $5.27B | $21.45B |
| Net Income (TTM) | $134M | $1.52B | $6.78B | $363M | $1.70B |
| Gross Margin | 10.6% | 67.6% | 41.5% | 15.2% | 42.8% |
| Operating Margin | 5.8% | 11.5% | 15.8% | 8.5% | 16.1% |
| Forward P/E | 13.1x | 7.3x | 14.2x | 23.2x | 10.9x |
| Total Debt | $3.70B | $5.51B | $50.20B | $4.15B | $13.17B |
| Cash & Equiv. | $27M | $138M | $1.04B | $504M | $2.88B |
SEM vs UHS vs HCA vs ENSG vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Select Medical Hold… (SEM) | 100 | 189.2 | +89.2% |
| Universal Health Se… (UHS) | 100 | 161.7 | +61.7% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
| Tenet Healthcare Co… (THC) | 100 | 892.1 | +792.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SEM vs UHS vs HCA vs ENSG vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SEM ranks third and is worth considering specifically for dividends.
- 1.5% yield, vs ENSG's 0.1%, (1 stock pays no dividend)
UHS is the clearest fit if your priority is value.
- Lower P/E (7.3x vs 23.2x), PEG 0.46 vs 1.68
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 9.0% margin vs SEM's 2.4%
- Beta 0.29 vs THC's 0.71
ENSG is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- Lower volatility, beta 0.42, current ratio 1.42x
- 18.7% revenue growth vs THC's 3.1%
- +27.5% vs UHS's -8.2%
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs ENSG's 7.5%
- PEG 0.33 vs ENSG's 1.68
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs THC's 3.1% | |
| Value | Lower P/E (7.3x vs 23.2x), PEG 0.46 vs 1.68 | |
| Quality / Margins | 9.0% margin vs SEM's 2.4% | |
| Stability / Safety | Beta 0.29 vs THC's 0.71 | |
| Dividends | 1.5% yield, vs ENSG's 0.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +27.5% vs UHS's -8.2% | |
| Efficiency (ROA) | 11.3% ROA vs SEM's 2.3%, ROIC 19.9% vs 4.8% |
SEM vs UHS vs HCA vs ENSG vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SEM vs UHS vs HCA vs ENSG vs THC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 2 of 6 categories
HCA leads 1 • SEM leads 0 • UHS leads 0 • ENSG leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 14.3x ENSG's $5.3B. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to SEM's 2.4%. On growth, ENSG holds the edge at +18.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.5B | $17.8B | $75.6B | $5.3B | $21.5B |
| EBITDAEarnings before interest/tax | $465M | $2.7B | $15.5B | $558M | $4.3B |
| Net IncomeAfter-tax profit | $134M | $1.5B | $6.8B | $363M | $1.7B |
| Free Cash FlowCash after capex | $117M | $894M | $7.7B | $406M | $3.3B |
| Gross MarginGross profit ÷ Revenue | +10.6% | +67.6% | +41.5% | +15.2% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +5.8% | +11.5% | +15.8% | +8.5% | +16.1% |
| Net MarginNet income ÷ Revenue | +2.4% | +8.6% | +9.0% | +6.9% | +7.9% |
| FCF MarginFCF ÷ Revenue | +2.1% | +5.0% | +10.2% | +7.7% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.0% | +9.6% | +6.7% | +18.4% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -18.2% | +17.7% | +44.6% | +21.9% | +87.6% |
Valuation Metrics
Evenly matched — SEM and UHS each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 75% valuation discount to ENSG's 29.8x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs ENSG's 2.16x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.0B | $10.7B | $95.9B | $10.2B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $5.7B | $16.0B | $145.1B | $13.8B | $27.3B |
| Trailing P/EPrice ÷ TTM EPS | 13.93x | 7.38x | 15.12x | 29.85x | 12.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.06x | 7.30x | 14.19x | 23.19x | 10.94x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.46x | 0.72x | 2.16x | 0.38x |
| EV / EBITDAEnterprise value multiple | 12.04x | 6.14x | 9.37x | 25.71x | 6.34x |
| Price / SalesMarket cap ÷ Revenue | 0.37x | 0.61x | 1.27x | 2.01x | 0.80x |
| Price / BookPrice ÷ Book value/share | 1.00x | 1.48x | — | 4.59x | 1.97x |
| Price / FCFMarket cap ÷ FCF | 5.33x | 12.57x | 12.47x | 27.46x | 6.72x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $7 for SEM. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs ENSG's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.6% | +20.7% | — | +16.6% | +19.6% |
| ROA (TTM)Return on assets | +2.3% | +9.8% | +11.3% | +6.8% | +5.7% |
| ROICReturn on invested capital | +4.8% | +12.3% | +19.9% | +7.0% | +13.2% |
| ROCEReturn on capital employed | +7.0% | +16.0% | +27.0% | +10.2% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 7 | 5 | 7 |
| Debt / EquityFinancial leverage | 1.82x | 0.74x | — | 1.86x | 1.47x |
| Net DebtTotal debt minus cash | $3.7B | $5.4B | $49.2B | $3.7B | $10.3B |
| Cash & Equiv.Liquid assets | $27M | $138M | $1.0B | $504M | $2.9B |
| Total DebtShort + long-term debt | $3.7B | $5.5B | $50.2B | $4.2B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | 4.41x | 10.92x | 5.37x | 88.33x | 4.28x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $8,886 for SEM. Over the past 12 months, ENSG leads with a +27.5% total return vs UHS's -8.2%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs SEM's 2.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +11.4% | -22.3% | -8.6% | +0.3% | -2.7% |
| 1-Year ReturnPast 12 months | +11.1% | -8.2% | +19.7% | +27.5% | +27.4% |
| 3-Year ReturnCumulative with dividends | +7.4% | +20.8% | +57.4% | +88.9% | +178.5% |
| 5-Year ReturnCumulative with dividends | -11.1% | +12.5% | +109.7% | +103.2% | +190.4% |
| 10-Year ReturnCumulative with dividends | +158.5% | +30.8% | +450.5% | +752.0% | +523.4% |
| CAGR (3Y)Annualised 3-year return | +2.4% | +6.5% | +16.3% | +23.6% | +40.7% |
Risk & Volatility
Evenly matched — SEM and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than THC's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs UHS's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 0.60x | 0.29x | 0.42x | 0.71x |
| 52-Week HighHighest price in past year | $16.99 | $246.33 | $556.52 | $218.00 | $247.21 |
| 52-Week LowLowest price in past year | $11.65 | $152.33 | $330.00 | $133.81 | $146.60 |
| % of 52W HighCurrent price vs 52-week peak | +96.8% | +69.2% | +77.1% | +80.0% | +78.5% |
| RSI (14)Momentum oscillator 0–100 | 60.9 | 39.7 | 30.8 | 23.3 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 793K | 1000K | 358K | 1.2M |
Analyst Outlook
Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SEM as "Hold", UHS as "Hold", HCA as "Buy", ENSG as "Buy", THC as "Buy". Consensus price targets imply 38.1% upside for THC (target: $268) vs 9.5% for SEM (target: $18). For income investors, SEM offers the higher dividend yield at 1.55% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $231.50 | $527.45 | $222.33 | $268.00 |
| # AnalystsCovering analysts | 13 | 43 | 46 | 13 | 32 |
| Dividend YieldAnnual dividend ÷ price | +1.5% | +0.5% | +0.7% | +0.1% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 5 | 12 | 0 |
| Dividend / ShareAnnual DPS | $0.25 | $0.80 | $2.94 | $0.24 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.9% | +9.1% | +10.5% | +0.2% | +8.4% |
THC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). HCA leads in 1 (Profitability & Efficiency). 3 tied.
SEM vs UHS vs HCA vs ENSG vs THC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SEM or UHS or HCA or ENSG or THC a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus 3. 1% for Tenet Healthcare Corporation (THC). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate HCA Healthcare, Inc. (HCA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SEM or UHS or HCA or ENSG or THC?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus The Ensign Group, Inc. at 29. 8x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus The Ensign Group, Inc. 's 1. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SEM or UHS or HCA or ENSG or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -11. 1% for Select Medical Holdings Corporation (SEM). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus UHS's +30. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SEM or UHS or HCA or ENSG or THC?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Tenet Healthcare Corporation's 0. 71β — meaning THC is approximately 147% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SEM or UHS or HCA or ENSG or THC?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus 3. 1% for Tenet Healthcare Corporation (THC). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SEM or UHS or HCA or ENSG or THC?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 2. 7% for Select Medical Holdings Corporation — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus 6. 1% for SEM. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SEM or UHS or HCA or ENSG or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus The Ensign Group, Inc. 's 1. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 23. 2x for The Ensign Group, Inc. — 15. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 38. 1% to $268. 00.
08Which pays a better dividend — SEM or UHS or HCA or ENSG or THC?
In this comparison, SEM (1.
5% yield), HCA (0. 7% yield), UHS (0. 5% yield), ENSG (0. 1% yield) pay a dividend. THC does not pay a meaningful dividend and should not be held primarily for income.
09Is SEM or UHS or HCA or ENSG or THC better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, UHS: +30. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SEM and UHS and HCA and ENSG and THC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SEM is a small-cap deep-value stock; UHS is a mid-cap deep-value stock; HCA is a mid-cap deep-value stock; ENSG is a mid-cap high-growth stock; THC is a mid-cap deep-value stock. SEM, HCA pay a dividend while UHS, ENSG, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.